Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D010096:Oxprenolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012008:Recurrence; D013015:Sotalol / Q000627:therapeutic use; D013999:Timolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D010096:Oxprenolol; D013999:Timolol; D011433:Propranolol; D013015:Sotalol; D008790:Metoprolol; D011217:Practolol